UNASSIGNED: 5073 Background: For @entity43 ( @entity43 ), a longer duration of response after second-line intravenous (IV) therapy as compared to first-line (IV) @entity902 therapy occurs in only 3% of @entity1 (Markman et al., 2004). The purpose of this study was to examine the time to progression interval (TPI) in @entity1 treated with surgery and intraperitoneal (IP) chemotherapy for first recurrence of their disease. METHODS: We retrospectively reviewed the medical records at our institution for @entity1 treated with second-line IP chemotherapy between January 2005 and April 2010. TPI was defined as the time from the end of previous therapy to the start of next therapy for both first-line and second-line @entity902 therapy. RESULTS: We identified 56 @entity1 who received second-line IP chemotherapy for their @entity43 recurrence. All @entity1 had previously undergone primary surgical cytoreduction (82.3% were considered optimally cytoreduced) followed by IV @entity902 -based chemotherapy. The mean age was 56.7 years (range 43-79). All @entity1 underwent secondary cytoreduction at the time of IP port placement for treatment of recurrent disease and 65.3% of @entity1 were considered optimally cytoreduced (< 1 cm @entity66 ) at the end of the secondary debulking surgery. In 13 @entity1 (23.2%) a longer TPI after second-line IP chemotherapy was observed compared to TPI after primary IV chemotherapy. The median first-line TPI for those 13 @entity1 was only 8 months, while median TPI after second-line IP chemotherapy was 24 months. In comparison, the 43 @entity1 with shorter TPI after IP chemotherapy had median TPI of 22.5 mos after first-line IV chemotherapy and 8 months after IP chemotherapy. CONCLUSIONS: A longer duration of second-line response was observed in 23.2% of @entity1 treated with IP chemotherapy after IV chemotherapy and the duration of response was clinically significant. The use of IP @entity902 treatment for recurrent @entity43 should be further studied in a prospective trial in @entity1 who do not do receive front-line IP @entity902 chemotherapy.

Extended duration of response with second-line intraperitoneal XXXX -based therapy for @entity43 .

@entity43 :: ('MESH:D010051', 'Disease') :: ['EOC', 'epithelial ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease']
@entity902 :: (MESH:D010984,Chemical) :: ['platinum']
